Ignite Creation Date:
2024-05-05 @ 10:40 PM
Last Modification Date:
2024-10-26 @ 10:22 AM
Study NCT ID:
NCT01163058
Status:
UNKNOWN
Last Update Posted:
2010-07-29
First Post:
2010-06-29
Brief Title:
Tyrosine Kinase Inhibitors In Metastatic Non Small Cell Lung Cancer
Sponsor:
Istituto Clinico Humanitas
Organization:
Istituto Clinico Humanitas
Study Overview
Official Title:
Retrospective Analysis Evaluating Molecular Factors of Primary Resistance to Tyrosine Kinase Inhibitors in Metastatic Non Small Cell Lung Cancer Patients
Status:
UNKNOWN
Status Verified Date:
2010-07
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Aim of the present retrospective study is to evaluate molecular factors of primary resistance to tyrosine kinase inhibitors in metastatic non small cell lung cancer NSCLC patients The investigators assess first the incidence of epidermal growth factor receptor EGFR and Kirsten ras sarcoma viral oncogene homolog KRAS mutations SOS and hepatocyte growth factor HGF expression anaplastic lymphoma kinase ALK translocation and expression and secondly the investigators correlate molecular markers with clinical features and outcome in terms of response rate progression free survival and overall survival
Detailed Description:
Non small cell lung cancer patients
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None